Navigation Links
SI-BONE, Inc. Announces Spring Society Meeting Attendance

SAN JOSE, Calif., March 4, 2013 /PRNewswire/ -- SI-BONE, Inc. (San Jose, California), a medical device company that is pioneering the use of a minimally invasive surgical (MIS) device to fuse the sacroiliac (SI) joint announced today it will attend and exhibit at several major society meetings over the coming months including AANS/CNS Section, AAOS, ISASS and AANS.  Later this week, the company will exhibit at the AANS/CNS Section Meeting on March 7th and 8th at the JW Marriott Desert Ridge in Phoenix, AZ in booth #100.  As part of the AANS/CNS Section meeting, Dr. William Smith * from Las Vegas, NV will be speaking during the David Cahill Memorial Controversies session Saturday morning, March 9th on the benefits of MIS SI joint fusion for SI joint disorders.  Later this month, SI-BONE will exhibit at the AAOS meeting from March 20th through 22nd in Chicago, IL in booth #655. 

"We are excited to be supporting the Academy by attending and exhibiting at their annual meeting and we are looking forward to the opportunity to educate this diverse group of orthopedic specialists on the diagnosis and treatment of SI joint disorders," said Jeffrey Dunn , President and CEO of SI-BONE.  Following AAOS, the company will exhibit at ISASS in Vancouver, Canada from April 3rd through April 5th in booth #109.  Three abstracts have been accepted and will be presented during poster sessions, including two by Dr. Leonard Rudolf *1,2 and one by Dr. Donald Sachs *3 on their respective clinical outcomes treating patients with iFuse.  Finally, at the end of April, the company will exhibit at the AANS meeting in New Orleans, LA from April 29th through May 1st in booth #1142.  During the meeting, Dr. Donald Sachs will present his clinical outcomes with iFuse during a poster session.  Mr. Dunn commented: "These next few months provide a great opportunity for us to support these key societies and continue our mission to educate and collaborate with their membership on advancing the diagnosis and treatment of patients who suffer from SI joint disorders."

SI-BONE, Inc. received original clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System for fracture fixation of long bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, and an additional clearance in April 2011 for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The CE mark for European commercialization was obtained in November 2010.

Clinical publications have identified the SI joint as a pain generator for up to 22% of low back pain patients.4  In addition, DePalma et al, Pain Medicine 2011, identified the SI joint as a pain generator in low back pain in 40 to 61% of post-lumbar fusion patients, so-called "failed back surgery" patients.5  Initial treatment options for patients with SI joint disorders typically involve non-surgical management and, when non-surgical treatment of the SI joint fails, surgical treatments such as the iFuse may provide an option.

The iFuse Implant System is a commercially available device in the U.S. and Europe.   The iFuse procedure uses a small incision for delivery and implantation of titanium implants.  The implants are coated with a porous, titanium plasma spray that acts as an interference surface, designed to help decrease implant motion and provide immediate fixation and long term fusion. These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional screws used to surgically fix bony structures.  The iFuse System is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.  As with all surgical procedures and permanent implants, there are risks and considerations associated with surgery and use of the iFuse Implant.

About SI-BONE, Inc.

SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to SI joint disorders.  The company has developed, and is manufacturing and marketing, a less invasive approach using implants for the treatment of certain SI joint pathologies.  SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.  SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2013 SI-BONE, Inc. All Rights Reserved. 8412.030113

*Physicians who also receive compensation from SI-BONE for providing consulting services.

1Rudolf Abstract: A-506-0000-00032. Title: "MIS Sacroiliac (SI) Joint Fusion in the Context of Previous Lumbar Spine Fusion: 50 Patients with 24 Month Follow up".  SI-BONE provided support for this study.

2Rudolf Abstract: A-506-0000-00031. Title: "Sacroiliac Joint Arthrodesis - MIS Technique with Titanium Implants: Report of the First 50 Patients and Outcomes with Minimum 24 Month Follow up".  SI-BONE provided support for this study.

3Sachs Abstract: A-506-0000-00500. Title: "One Year Successful Outcomes for Novel Sacroiliac Joint Arthrodesis System".  SI-BONE provided support for this study.

4 Bernard TN, Kirkaldy-Willis WH. Recognizing specific characteristics of nonspecific low back pain. Clinical Orthopedics 1987;217:266–80.

5 DePalma, M. Etiology of chronic LBP patients having undergone lumbar fusion. Pain Medicine, 2011;12:732-39.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
Breaking Medicine News(10 mins):